NCT00102297已完成1 期
A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects With Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Kyntra Bio
- 入组人数
- 20
- 试验地点
- 10
- 主要终点
- Safety
研究概览
简要总结
The Phase 1b study is a multi-center trial designed to test the safety, tolerability, biologic activity of escalating doses of FG-3019 in up to 20 patients with type 1 or type 2 diabetes and microalbuminuria (early-stage kidney disease). Patients will receive either 3 or 10 mg/kg of FG-3019 administered every two weeks as an infusion for a total of four doses. The ability of FG-3019 to reduce the excretion of protein in the urine is being measured as a secondary endpoint.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Body mass index not exceeding 32.0 kg/m2
- •If female, subject must meet one of the following criteria: a) surgically sterile (hysterectomy or bilateral tubal ligation) OR b) at least two years postmenopausal OR c) using a dual method of contraception and have a negative serum pregnancy test if of childbearing potential
- •Diagnosis of type 1 or type 2 diabetes according to the American Diabetes Association
- •Fasting plasma glucose of ≥ 126 mg/dL or current treatment with oral hypoglycemic agents or insulin
- •Microalbuminuria defined as albumin to creatinine ratio in a spot collection (first void) of 30 - 300 mg/gram confirmed by two samples two to three days apart
- •Serum creatinine of no more than 1.5 mg/dL for men and no more than 1.1 mg/dL for women
排除标准
- •Female subjects who are pregnant or lactating
- •Non-diabetic renal disease
- •History of allergic or anaphylactic reaction to human, humanized, chimeric, or murine monoclonal antibodies
- •Coronary artery bypass graft surgery, myocardial infarction, cerebrovascular accident, percutaneous transluminal angioplasty, transient ischemic attack, history of unstable angina, known heart failure, uncontrolled cardiac arrhythmia, or uncontrolled hypertension within six months prior to Day 0
- •Bilirubin, aspartate aminotransferase (AST), or alanine aminotransferase (ALT) > 1.5 times the upper limit of normal
- •History of cancer of any type in the past 5 years, except non- melanomatous skin cancer, localized bladder cancer, or in situ cervical cancer.
- •Clinically significant and uncontrolled medical condition considered a high risk for participation in an investigational study
- •Trauma or surgical procedures (including dental) within six months prior to Day 0
- •Planned elective surgery during the study and for 3 months following the end of the study
- •Participation in studies of investigational drugs within 6 weeks prior to first dose
结局指标
主要结局
Safety
Tolerability
Pharmacokinetics
次要结局
- Bioactivity on urinary and plasma markers
研究者
研究点 (10)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQPMalariaNCT03542149Medicines for Malaria Venture24
终止
1 期
A Study of TAS1440 With ATRA in Subjects With r/r AMLAcute Myeloid LeukemiaNCT04282668Taiho Oncology, Inc.52
已完成
1 期
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)Myelodysplastic Syndromes (MDS)NCT02966782AbbVie70
进行中（未招募）
1 期
Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDACMetastatic Pancreatic CancerNCT06059001Peptomyc S.L.26
已完成
1 期
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)Multiple MyelomaNCT02431208Hoffmann-La Roche85